{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:36:41Z","timestamp":1777909001605,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Living Cell Technologies"},{"name":"Edmond J. Safra Foundation"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.parkreldis.2020.12.005","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T05:32:12Z","timestamp":1607578332000},"page":"128-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["A long-term follow-up of safety and clinical efficacy of NTCELL\u00ae [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease"],"prefix":"10.1016","volume":"82","author":[{"given":"Eoin","family":"Mulroy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Bok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.B. Janice","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Finucane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schweder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.005_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.12.005_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/mds.27383","article-title":"Disease modification for Parkinson's disease: Axonal regeneration and trophic factors","volume":"33","author":"Kordower","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.12.005_bib3","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.parkreldis.2007.06.003","article-title":"The economic impact of Parkinson's disease","volume":"13","author":"Findley","year":"2007","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.005_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.69.3.308","article-title":"What contributes to quality of life in patients with Parkinson's disease?","volume":"69","author":"Schrag","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.12.005_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/14728222.12.4.437","article-title":"Neurotrophic factors as a therapeutic target for Parkinson's disease","volume":"12","author":"Evans","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"issue":"12","key":"10.1016\/j.parkreldis.2020.12.005_bib6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.005_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"Lang","year":"2006","journal-title":"Ann. Neurol."},{"issue":"13","key":"10.1016\/j.parkreldis.2020.12.005_bib8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1212\/WNL.0b013e3182a55ea5","article-title":"Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation","volume":"81","author":"Patel","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.005_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.parkreldis.2020.12.005_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","article-title":"Delivery of neurotrophic factors to the central nervous system","volume":"40","author":"Thorne","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.12.005_bib11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line\u2013derived neurotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.005_bib12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awz023","article-title":"Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease","volume":"142","author":"Whone","year":"2019","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.005_bib13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.21032","article-title":"Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys","volume":"60","author":"Kordower","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2020.12.005_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.parkreldis.2018.11.015","article-title":"A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL\u00ae [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease","volume":"61","author":"Snow","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.005_bib15","doi-asserted-by":"crossref","DOI":"10.1088\/1741-2560\/6\/6\/065001","article-title":"Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma","volume":"6","author":"Skinner","year":"2009","journal-title":"J. Neural. Eng."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.005_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JPD-130214","article-title":"Recovery of neurological functions in non-human primate model of Parkinson's disease by transplantation of encapsulated neonatal porcine choroid plexus cells","volume":"3","author":"Luo","year":"2013","journal-title":"J. Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.12.005_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/rme.11.15","article-title":"Restoration of motor control and dopaminergic activity in rats with unilateral 6-hydroxy-dopamine lesions - Retracted","volume":"6","author":"Skinner","year":"2011","journal-title":"Regen. Med."},{"issue":"16","key":"10.1016\/j.parkreldis.2020.12.005_bib18","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/00001756-200411150-00018","article-title":"Neuroprotection by encapsulated choroid plexus in a rodent model of Huntington's disease","volume":"15","author":"Borlongan","year":"2004","journal-title":"Neuroreport"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2020.12.005_bib19","first-page":"321","article-title":"Safety and clinical effects of NTCELL\u00ae [immunoprotected (alginate- encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease (PD): 26 weeks follow-up [abstract]","volume":"30","author":"Snow","year":"2015","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.12.005_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C","article-title":"Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)","volume":"14","author":"Defer","year":"1999","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.12.005_bib21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/xen.12060_27","article-title":"Oral communication 8: tg pigs and animal models","volume":"20","author":"Luo","year":"2013","journal-title":"Xenotransplantation"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.12.005_bib22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41582-019-0180-6","article-title":"Parkinson disease and growth factors \u2014 is GDNF good enough?","volume":"15","author":"Kirkeby","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.12.005_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JPD-191576","article-title":"Extended treatment with glial cell line-derived neurotrophic factor in Parkinson's disease","volume":"9","author":"Whone","year":"2019","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.12.005_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","article-title":"Point source concentration of GDNF may explain failure of phase II clinical trial","volume":"202","author":"Salvatore","year":"2006","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2020.12.005_bib25","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/mds.27790","article-title":"Measuring Parkinson's disease over time: the real\u2010world within\u2010subject reliability of the MDS\u2010UPDRS","volume":"34","author":"Evers","year":"2019","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.12.005_bib26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.26642","article-title":"Technology in Parkinson's disease: challenges and opportunities","volume":"31","author":"Espay","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.12.005_bib27","first-page":"1","article-title":"Forecasts for the Attainment of major research milestones in Parkinson's disease","author":"Kane","year":"2020","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.12.005_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1474-4422(02)00038-8","article-title":"The placebo effect in neurological disorders","volume":"1","author":"de la Fuente-Fern\u00e1ndez","year":"2002","journal-title":"Lancet Neurol."},{"issue":"163","key":"10.1016\/j.parkreldis.2020.12.005_bib29","doi-asserted-by":"crossref","first-page":"163ra156","DOI":"10.1126\/scitranslmed.3004676","article-title":"-Synuclein-Induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci. Transl. Med."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020309032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020309032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:21:33Z","timestamp":1761178893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020309032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S1353802020309032"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A long-term follow-up of safety and clinical efficacy of NTCELL\u00ae [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}